Added to YB: 2026-04-22
Pitch date: 2026-04-20
KYMR [neutral]
Kymera Therapeutics, Inc.
+1.07%
current return
Author Info
No bio for this author
Company Info
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
Market Cap
$7.2B
Pitch Price
$87.14
Price Target
140.00 (+61%)
Dividend
N/A
EV/EBITDA
-17.41
P/E
-23.80
EV/Sales
143.42
Sector
Biotechnology
Category
growth
Monthly Core Conviction #1: KYMR and The Full M&A Book
KYMR (update): Oral protein degrader platform targeting immunology. Lead asset KT-621 (STAT6 degrader) in Phase 2b for AD (mid-2027) & eosinophilic asthma (late 2027); could rival $12B+ Dupixent w/ oral delivery. KT-579 (IRF5 degrader) Phase 1 data 2H26. Gilead paid $45M for CDK2 option, Sanofi partnered IRAK4. $1.6B cash, runway to 2029. PT $140 (+60%). M&A likely post Phase 2b data. Risk: binary clinical readouts
Read full article (3 min)